Vipivotide tetraxetan Linker

• CAT Number: I018760
• CAS Number: 1703768-74-4
• Molecular Formula: C₃₃H₄₅N₅O₉
• Molecular Weight: 655.74
• Purity: ≥95%
• Target: ADC Linker
• IUPAC Name: (2S)-2-[[(1S)-5-[[(2S)-2-[[4-(aminomethyl)cyclohexanecarbonyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-1-carboxypentyl]carbamoylamino]pentanedioic acid
• InChI: InChI=1S/C33H45N5O9/c34-19-20-8-12-23(13-9-20)29(41)36-27(18-21-10-11-22-5-1-2-6-24(22)17-21)30(42)35-16-4-3-7-25(31(43)44)37-33(47)38-26(32(45)46)14-15-28(39)40/h1-2,5-6,10-11,17,20,23,25-27H,3-4,7-9,12-16,18-19,34H2,(H,35,42)(H,36,41)(H,39,40)(H,43,44)(H,45,46)(H2,37,38,47)/t20?,23?,25-,26-,27-/m0/s1
• InChIKey: JHWCOTSIOATVKA-MOTXCXSHSA-N
• SMILES: C1CC(CCC1CN)C(=O)NC(CC2=CC3=CC=CC=C3C=C2)C(=O)NCCCCC(C(=O)O)NC(=O)NC(CCC(=O)O)C(=O)O

Vipivotide tetraxetan linker（Cat No.:I018760）, also known as PSMA-617 linker, is a potent non-degradable peptide linker utilized for the synthesis of Vipivotide tetraxetan (PSMA-617). Vipivotide tetraxetan serves as a ligand in the production of 177Lu-PSMA-617, a radioactive molecule employed in prostate cancer research. The conjugation of Vipivotide tetraxetan with the radioactive isotope lutetium-177 enables specific targeting of prostate-specific membrane antigen (PSMA), a protein overexpressed in prostate cancer cells. This targeted therapy has shown promise in improving the diagnosis and treatment of prostate cancer.

Reference

[1]. Benešová M, et al. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile. Mol Pharm. 2018 Mar 5;15(3):934-946.